Covidien pursues $3B share buyback; Hologic unloads business line for $85M;

 @FierceMedDev: Cornell: Metal stents work well as blocked bile duct treatment. Item | Follow @FierceMedDev

 @MarkHFierce: Third Rock is rolling out a new $516M VC fund, for device, Dx and biotech companies. Target: early-stage companies. Release | Follow @MarkHFierce

 @DamianFierce: Abbott is warning overseas surgeons about a safety issue with MitraClip, all as it seeks FDA approval. Report | Follow @DamianFierce

> Covidien ($COV) will launch a new effort to buy back up to $3 billion of its shares, on top of a $2 billion share repurchase program under way since August 2011. Release

> Hologic ($HOLX), a maker of diagnostics, medical imaging systems and surgical tools focused on women, has completed the $85 million sale of its LIFECODES business to Immucor. Item

> Cambridge Cognition, a maker of neuropsychological diagnostic tests, will pursue an IPO in the U.K. Story

> CardioDx, a 2012 Fierce 15 company, generated promising data in a recent trial that showed its Corus CAD was more accurate in diagnosing obstructive coronary artery disease in women than evaluation of symptoms and myocardial perfusion imaging. Release

> SQI Diagnostics has completed a proof of concept test for two forms of heparin using its signature diagnostic tech. Item

> ConservoCare, a startup spun off from Case Western Reserve University, is developing a nerve stimulation device that helps treat bladder-control problems. Story

Biotech News

 @FierceBiotech: More on CRO shutdown from Former Cetero shutters ops, leaving sponsors, patients locked out. Story | Follow @FierceBiotech

@JohnCFierce: Third Rock Ventures adds $516M fund to back new portfolio of biotechs. News | Follow @JohnCFierce

@RyanMFierce: Astellas Pharma taps supercomputer for IT-driven drug discovery. More | Follow @RyanMFierce

> Versant adds $7.5M to upstart biotech's A round. Story

> Strike two: FDA hands United Therapeutics another rejection on oral Remodulin. Article

> Novartis snags FDA approval for antibiotic in CF patients. Story

Pharma News

@FiercePharma: Interesting look at Big Pharma's new-drug sales, a.k.a Freshness Index, from Forbes columnist Bernard Munos. Report | Follow @FiercePharma

@EricPFierce: Actavis getting nearly $3 million from taxpayers to expand a plant in Florida. Story | Follow @EricPFierce

> Drugmakers on edge as pay-for-delay case hits Supreme Court. Item

> Early copies of Sanofi's Aubagio could roil European MS market. Article

> AstraZeneca zaps another Crestor generic threat with Actavis settlement. News

CRO News

> Bayer deepens Cambodian presence with DKSH partnership. More

> Sanofi beefs up CMO game with Transgene deal. Item

> Dr. Reddy's wins $22.5M from CRO Nordion. News

> Duke's in-house CRO snags trial deal for RNAi drug. Article

> ShangPharma wins investor vote for go-private plan. Story

Biotech IT News

> BlackBerry founder bets on quantum tech in life sciences. Item

> NextDocs and Microsoft pushing clinical trials to the cloud. Story

> AstraZeneca IT chief talks up Big Data amid R&D turmoil. Report

> Biotech data merges onto UC San Diego's Big Data "freeway." Article

> Merck slashes data-management costs with China site. More

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.